Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

The researchers who conducted the review said their findings suggest most people can eat red and processed meat at current average intake, typically three or four times a week for adults in North America and Europe, without significant health risks. “Based on the research, we cannot say with any certainty that eating red or processed meat causes cancer, diabetes or heart disease,” said Bradley Johnston, an associate professor at Dalhousie University in Canada who co-led the review published on Monday in the Annals of Internal Medicine journal. However, in what amounts to a scientific food fight, experts from Harvard, Yale, Stanford and elsewhere, including one of the review authors, said guidelines that could lead people to eat more red and processed meats were irresponsible. They asked in a letter to the journal that it “pre-emptively retract publication” of the papers pending further review. A statement by the Harvard School of Public Health, shared with Reuters by Frank Hu, a doctor and chair of the nutrition department, said: “From a public health point of view, it is irresponsible and unethical to issue dietary guidelines that are tantamount to promoting meat consumption, even if there is still some uncertainty about the strength of the evidence.”  The World Health Organization’s International Agency for Research on Cancer (IARC) and the World Cancer Research Fund (WCRF) both say red and processed meat may or can cause cancer. The WCRF advises eating “little, if any” processed meat and only “moderate amounts” of red meat, such as beef, pork and lamb - with a weekly limit of 500 grams (17.6 ounces) cooked weight. Giota Mitrou, the WCRF’s director of research, said people should not misinterpret the review as saying meat is risk-free. “The public could be put at risk if they interpret this new recommendation to mean we can continue eating as much red and processed meat as they like without increasing their risk of cancer,” she said. “This is not the case.”          In the analysis published on Monday, researchers from Canada, Spain and Poland conducted a series of reviews of both randomized controlled trials and observational studies looking at the possible health impact of eating red and processed meat. Among the randomised trials they selected for analysis, which included around 54,000 people, they found no statistically significant link between eating meat and the risk of heart disease, diabetes, or cancer. Among the observational studies, which covered millions of people, they did find “a very small reduction in risk” in those who ate three fewer servings of red or processed meat a week, but said this association “was very uncertain.”  “Our bottom line recommendation ... is that for the majority of people, but not everyone, continuing their red and processed meat consumption is the best approach,” Johnston said. David Katz, director of the Yale-Griffin Prevention Research Center at the Yale University School of Medicine, said he had “grave concerns” about the potential of the new review “for damage to public understanding, and public health”. But other experts said the work was a comprehensive, well-conducted analysis of the available evidence on eating meat and human health. “This study will, I hope, help to eliminate the incorrect impression ... that some meat products are as carcinogenic as cigarette smoke, and to discourage dramatic media headlines claiming that ‘bacon is killing us’,” said Ian Johnson, a nutrition expert at Britain’s Quadram Institute of bioscience. Christine Laine, editor in chief of Annals of Internal Medicine, noted that nutrition studies are challenging. “To be honest with our patients and the public, we shouldn’t be making recommendations that sound like they’re based on solid evidence,” she said. “There may be lots of reasons to decrease meat in your diet, but if you’re decreasing it to improve your health, we don’t have a lot of strong evidence to support that.”
Steak is back on the menu, if a new red meat risk review is to be believed.

The company’s forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain’s second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year. Top-selling Crestor, for high cholesterol, faces competition from cheap copycat drugs in 2016. The patent expiries leave AstraZeneca’s sales on a near-term downward spiral at a time when most of its rivals have put their biggest patent losses behind them. Shares in the group rose 1.6 percent by 1215 GMT on the more upbeat outlook, against a 0.3 percent decline for the European healthcare sector. Chief Executive Pascal Soriot, who has been leading the company for a little more than a year, will set out the new revenue guidance in a presentation at the J.P. Morgan Healthcare conference in San Francisco later on Tuesday. The company will then give a more detailed update on its progress in full-year results on February 6. The consensus of analyst forecasts compiled by Thomson Reuters is for 2017 revenue of $22.5 billion, down from the $25.8 billion estimated for 2013. However, a number of the 2017 forecasts pre-date the diabetes drug deal struck last month that is already expected to add some $1 billion to $2 billion to annual revenue. Citigroup analyst Andrew Baum said the positive medium-term outlook reinforced his “more constructive thesis” for the stock, adding that he expects Soriot to strike more earnings-boosting deals this year. Panmure Gordon’s Savvas Neophytou remains more wary, pointing out that Soriot’s predecessor, David Brennan, had made a similar attempt to talk up AstraZeneca’s longer-term prospects. “In our view, management is stepping onto thin ice with this same sort of guidance,” Neophytou said, pointing out the previous management’s failure to hit its forecasts. AstraZeneca has become more confident about its revenue outlook after the $4 billion deal last month to buy Bristol-Myers Squibb’s share of a diabetes joint venture. The acquisition is expected to complete in the first quarter of 2014 and will boost sales immediately. Mark Clark of Deutsche Bank said this was set to lift analysts’ revenue forecasts significantly, suggesting that a more realistic “adjusted consensus” for 2017 was around $24.3 billion rather than $22.5 billion. Soriot has been striking a number of bolt-on deals to refill the company’s thin pipeline of new medicines and accelerating in-house research programs. The group now has 11 new-drug programs in late-stage Phase III testing, almost double the number a year ago, and 27 in Phase II. Hopes are particularly high for its cancer research, where it has started trials for immunotherapy combination treatments for which the first results are anticipated in 2014/15. AstraZeneca is behind the likes of Bristol-Myers, Roche and Merck & Co in the race to develop immunotherapies - a hot new area of cancer research - but it is betting on combination treatments to help it to catch up. Immunotherapy, which harnesses the body’s immune system to fight cancer, has shown great promise in clinical trials and analysts believe that the treatments may extend patients’ lives significantly and generate tens of billions of dollars in annual sales.
Drugmaker AstraZeneca forecasts faster return to growth.

The Yakima Health District said Thursday that the cases involve people experiencing homelessness or those who use illicit drugs. The health district announced the outbreak Nov. 7, when five cases were confirmed in Yakima County. Since then, various local agencies have done outreach and vaccinated 74 people. The virus affects the liver and spreads through contaminated feces. It causes symptoms like fever, dark urine, yellow-tinged skin or eyes, fatigue and gastric issues. People pass it along by eating or drinking tainted food or water, or through sex. On July 30, the Washington State Department of Health announced a multi-county hepatitis A outbreak. Through genetic testing, it was found that the Yakima County hepatitis A strain that is being observed is related to the hepatitis A outbreak in Spokane.

Hepatitis A outbreak increases to 11 cases in Yakima County.